165 related articles for article (PubMed ID: 13680158)
21. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470.
Devineni D; Klein-Szanto A; Gallo JM
Cancer Res; 1996 May; 56(9):1983-7. PubMed ID: 8616836
[TBL] [Abstract][Full Text] [Related]
22. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
Agarwala SS; Kirkwood JM
Oncologist; 2000; 5(2):144-51. PubMed ID: 10794805
[TBL] [Abstract][Full Text] [Related]
23. A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.
Panetta JC; Kirstein MN; Gajjar AJ; Nair G; Fouladi M; Stewart CF
Math Biosci; 2003 Nov; 186(1):29-41. PubMed ID: 14527745
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of temozolomide in cancer patients.
Jen JF; Cutler DL; Pai SM; Batra VK; Affrime MB; Zambas DN; Heft S; Hajian G
Pharm Res; 2000 Oct; 17(10):1284-9. PubMed ID: 11145236
[TBL] [Abstract][Full Text] [Related]
25. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Broniscer A; Iacono L; Chintagumpala M; Fouladi M; Wallace D; Bowers DC; Stewart C; Krasin MJ; Gajjar A
Cancer; 2005 Jan; 103(1):133-9. PubMed ID: 15565574
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of dacarbazine (DTIC) in pregnancy.
Kantrowitz-Gordon I; Hays K; Kayode O; Kumar AR; Kaplan HG; Reid JM; Safgren SL; Ames MM; Easterling TR; Hebert MF
Cancer Chemother Pharmacol; 2018 Mar; 81(3):455-460. PubMed ID: 29305638
[TBL] [Abstract][Full Text] [Related]
27. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma.
Chowdhury SK; Laudicina D; Blumenkrantz N; Wirth M; Alton KB
J Pharm Biomed Anal; 1999 Apr; 19(5):659-68. PubMed ID: 10698531
[TBL] [Abstract][Full Text] [Related]
28. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of trabectedin in adolescent patients with cancer.
Poggesi I; Valenzuela B; Ouellet D; Gonzalez M; Hillewaert V; Baruchel S; Fox E; Perez-Ruixo JJ
Cancer Chemother Pharmacol; 2019 Oct; 84(4):707-717. PubMed ID: 31286189
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M
Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of simple step protein precipitation UHPLC-MS/MS methods for quantitation of temozolomide in cancer patient plasma samples.
El Mubarak MA; Stylos EK; Chatziathanasiadou MV; Danika C; Alexiou GA; Tsekeris P; Renziehausen A; Crook T; Syed N; Sivolapenko GB; Tzakos AG
J Pharm Biomed Anal; 2019 Jan; 162():164-170. PubMed ID: 30243056
[TBL] [Abstract][Full Text] [Related]
33. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.
Kearns GL; Robinson PK; Wilson JT; Wilson-Costello D; Knight GR; Ward RM; van den Anker JN;
Clin Pharmacol Ther; 2003 Oct; 74(4):312-25. PubMed ID: 14534518
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.
Tsang LL; Quarterman CP; Gescher A; Slack JA
Cancer Chemother Pharmacol; 1991; 27(5):342-6. PubMed ID: 1998993
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
Kerbusch T; de Kraker J; Mathĵt RA; Beijnen JH
Clin Pharmacokinet; 2001; 40(8):615-25. PubMed ID: 11523727
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K
Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
[TBL] [Abstract][Full Text] [Related]
38. Validated HPLC method for determination of temozolomide in human plasma.
Gilant E; Kaza M; Szlagowska A; Serafin-Byczak K; Rudzki PJ
Acta Pol Pharm; 2012; 69(6):1347-55. PubMed ID: 23285701
[TBL] [Abstract][Full Text] [Related]
39. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
40. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
